CD70: A potential target in breast cancer?

Journal of Cancer

Volumn 5, Issue 9, 2014, Pages 761-764

  Petrau, Camille ^a   Cornic, Marie ^a   Bertrand, Philippe ^b   Maingonnat, Catherine ^b   Marchand, Vinciane ^b   Picquenot, Jean Michel ^a,b   Jardin, Fabrice ^b   Clatot, Florian ^a,b  

^a CENTRE HENRI BECQUEREL   (France)

^b UNIVERSITY OF ROUEN   (France)

Author keywords

Antibody drug conjugate; Breast cancer; CD70; DNA methylation; mRNA expression; q RT PCR

Indexed keywords

BISULFITE; CD70 ANTIGEN; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; COLLOID CARCINOMA; DNA METHYLATION; DOWN REGULATION; FEMALE; HUMAN; IN VITRO STUDY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

EID: 84920920367     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.10360     Document Type: Article

References (19)

1. Pardoll DM. Cancer vaccines. Immunol Today. 1993;14(6):310-316.
2. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J Immunol Baltim Md 1950. 1994;152(4):1756-1761.
3. Grewal IS. CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 2008;12(3):341-351.
4. Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Hum Pathol. 2012;43(9):1394-1399.
5. Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti- CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010;103(5):676-684.
6. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 2002;62(9):2592- 2599.
7. Aulwurm S, Wischhusen J, Friese M, Borst J, Weller M. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer J Int Cancer. 2006;118(7):1728-1735.
8. Cormary C, Gonzalez R, Faye J-C, Favre G, Tilkin-Mariamé A-F. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther. 2004;11(7):497-507.
9. Douin-Echinard V, Péron J-M, Lauwers-Cancès V, Favre G, Couderc B. Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response. Int Immunol. 2003;15(3):359-372.
10. Rhee DK, Park SH, Jang YK. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. Genomics. 2008;92(6):419-428.
11. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus- inducing drugs. J Immunol Baltim Md 1950. 2005;174(10):6212-6219.
12. Yu SE, Park SH, Jang YK. Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Mol Cells. 2010;29(2):217-221.
13. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736-47.
14. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal- like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(5):1368-1376.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001;25(4):402-408.
16. Bertrand P, Maingonnat C, Penther D, Guney S, Ruminy P, Picquenot JM, et al. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2013;52(8):764-774.
17. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(19):6171-6180.
18. Law C-L, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 2006;66(4):2328-2337.
19. Liu N, Sheng X, Liu Y, Zhang X, Yu J. Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas. OncoTargets Ther. 2013;6:615-619.